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Abstract
Background: Endoglin (CD105) has been considered a prognostic marker for hepatocellular carcinoma
(HCC), and widely used as an appropriate targeting for antiangenesis therapy in some cancers. Our aim
was to evaluate the distribution and expression of CD105 in the liver of patients with HCC, and to discuss
whether CD105 may be used as an appropriate targeting for antiangenesis therapy in HCC.
Methods: Three parts of liver tissues from each of 64 patients with HCC were collected: tumor tissues
(TT), adjacent non-tumor (AT) liver tissues within 2 cm, and tumor free tissues (TF) 5 cm far from the
tumor edge. Liver samples from 8 patients without liver diseases served as healthy controls (HC). The
distribution and expression of CD105 in tissues were evaluated by immunohistochemistry, Western
blotting analysis, and real-time PCR. HIF-1alpha and VEGF165 protein levels in tissues were analyzed by
Immunohistochemistry and Western blotting analysis or ELISA.
Results: CD105 was positively stained mostly in a subset of microvessels 'endothelial sprouts' in TT of all
patients while CD105 showed diffuse positive staining, predominantly on hepatic sinus endothelial cells in
the surrounding of draining veins in TF and AT. The mean score of MVD-CD105 (mean ± SD/0.74 mm2)
was 19.00 ± 9.08 in HC, 153.12 ± 53.26 in TF, 191.12 ± 59.17 in AT, and 85.43 ± 44.71 in TT, respectively.
Using a paired t test, the expression of CD105 in AT and TF was higher than in TT at protein (MVD, p =
0.012 and p = 0.007, respectively) and mRNA levels (p < 0.001 and p = 0.009, respectively). Moreover,
distribution and expression of CD105 protein were consistent with those of HIF-1alpha and VEGF165
protein in liver of patients with HCC. The level of CD105 mRNA correlated with VEGF165 level in TF (r =
0.790, p = 0.002), AT (r = 0.723, p < 0.001), and TT (r = 0.473, p = 0.048), respectively.
Conclusion: It is demonstrated that CD105 was not only present in neovessels in tumor tissues, but also
more abundant in hepatic sinus endothelium in non-tumor tissues with cirrhosis. Therefore, CD105 may
not be an appropriate targeting for antiangenesis therapy in HCC, especially with cirrhosis.
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Background
Endoglin (CD105) is a homodimeric transmembrane
glycoprotein highly expressed on activated endothelial
cells, and is involved in vascular development and remod-
eling [1,2]. In line with these findings, compared to the
conventional biomarker CD34, CD105 has been demon-
strated to be a superior angiogenesis marker in breast can-
cer [3], malignant melanoma [4], non-small cell lung
cancer [5], and colorectal carcinoma [6]. These findings
have provided supportive evidence to the usefulness of
CD105 targeting in antiangiogenetic therapy of cancer
[7,8]. Seon's studies have demonstrated long-lasting com-
plete abrogation of human breast tumors in SCID mice
using CD105 antibody with immunotoxins [9,10] and
growth suppression of human solid tumors using radiola-
beled antibody to CD105 [11]. In a clinical investigation,
Costello et al reported that 99Tcm-labeled antibody to
CD105 had the ability of the specific localization in the
tumor vasculature of the kidneys [12].
As a typical hypervascular tumor, hepatocellular carci-
noma (HCC) is the most common hepatic malignancy
worldwide, especially in South-east Asia. Approximately
80% of HCC patients have been associated with liver cir-
rhosis [13]. Even after comprehensive therapies with sur-
gical excision, chemotherapy, ethanol injection,
radiofrequency, or cryotherapy, this tumor shows a high
percentage of recurrence and metastasis, and the mean
survival of the patients is still short, compared to other
major solid tumors. It is assumed that such high vascular-
ity could be one of the reasons responsible for the poor
prognosis [14]. Innovative approaches, such as targeting
the non-transformed, less resistant, tumor supporting
endothelial cells, may change this outcome [15]. Our pre-
vious investigation demonstrated the superiority of
CD105 to CD34 as a marker of angiogenesis in HCC,
which was consistent with the investigation of Ho
[16,17]. Therefore, we hypothesized that CD105 might be
an appropriate targeting for antiangiogenesis therapy in
HCC.
To validate the specificity of targeting for antiangenesis
therapy with CD105 in HCC, we further evaluated the dis-
tribution and expression of CD105 in liver with HCC at
protein and mRNA levels. Moreover, two relevant factors
with the expression of CD105, hypoxia inducing factor
1alpha (HIF-1alpha) and the 165-amino acid form of vas-
cular endothelial growth factor (VEGF165), were also eval-
uated at protein level.
Methods
Patients and tissue specimens
Sixty-four HCC patients, hospitalized in the Department
of Hepatobiliary Surgery of Drum Tower Hospital
between January 2004 and August 2006, were enrolled in
the present study. None of the patients had received pre-
operative treatment, such as transarterial chemoemboliza-
tion, et al. Normal liver tissues from 4 donors for liver
transplantation and 4 patients with no evidence of liver
diseases severed as healthy controls (HC). The research
ethics committee of Drum Tower hospital approved this
protocol and verbal consent was obtained from all partic-
ipants.
Tumor tissues (TT), adjacent non-tumor tissues (AT)
within 2 cm, and tumor free tissues (TF) more than 5 cm
far from the tumor edge were collected immediately after
surgical resection from each of the 64 HCC patients as
described by Mathonnet [18]. Necrotic or hemorrhagic
tissues were excluded. Tissues were snap-frozen and kept
in liquid nitrogen until use (protein and RNA isolation),
or were fixed in 10% formalin and embedded in paraffin
for immunohistochemical study and Hematoxylin and
Eosin stain (H&E). Four μm thick sections were prepared
and stained with H&E for study of the pathological fea-
tures of HCC in accordance with the Classification of Car-
cinomas of the Liver proposed by UICC [19].
Histopathological examination was evaluated by a senior
pathologist (Prof. Zhang), who was unaware of the results
of this study. Serial sections of the tumors and surround-
ing tissues were examined to identify any tumor encapsu-
lation, microscopic venous invasion, and microsatellite
lesions.
Immunohistochemical staining for CD105, HIF-1alpha and 
VEGF165
Consecutive paraffin sections from HC, TF, AT, and TT
were immunoassayed with the antibodies to human
CD105 (1:400, H-300, Santa Cruz, CA), HIF-1alpha
(1:400, Chemicon, CA), and VEGF165 (1:100, Santa Cruz).
A subsequent reaction was performed with biotin-free
HRP enzyme labeled polymer from an En Vision plus
detection system (DAKO, CA). Positive reactions were vis-
ualized with diaminobenzidine (DAB) solution followed
by counterstaining with hematoxylin. Negative controls
were performed using non-immune goat serum instead of
the primary antibodies.
Microvessel density (MVD) was evaluated according to
Gasparini's criteria by two independent investigators as
described in previous reports [20,21]. The mean microves-
sel count of the five most vascular areas was taken as the
MVD, which was expressed as the absolute number of
microvessels per 0.74 mm2 (×200 field) on an Olympus
microscope (CX-31) with an Olympus camera (C-5050Z).
For HIF-1alpha and VEGF165 analysis, 10 areas were ran-
domly selected and counted under a microscope at a mag-
nification of 200. According to the degree of distribution
of immunoreactive cells, HIF-1alpha and VEGF165 expres-
sion were graded into three levels: negative when theBMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
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stained cells were present in less than 10% of the entire
area; weakly positive when the stained cells were present
in 10% to 50%; and positive when the stained cells were
present in 50% or more.
Western blotting analysis
Tissues were ground to power with a mortar and pestle as
rapidly as possible in liquid nitrogen, washed with cold
PBS, and lysed with equal volumes of RIPA lysis buffer (50
mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% NaN3, 1%
Triton X-100, 1% SDS) with Cocktail protease inhibitor
(1:200, Sigma, St Louis) on ice for 30 min, and then son-
icated four times for 5 s each. Tissue lysates obtained fol-
lowing centrifugation (12,000 × g, 4°C, 10 min), were
subjected to Western blotting analysis.
Protein was quantified using the Coomassie plus protein
assay reagent (Pierce Chemical Co, IL) and adjusted to an
equal concentration for each sample before electrophore-
sis. The lysates were heated in Laemmli buffer at 95°C,
resolved by 8% SDS-PAGE gel (Amresco, Ohio), trans-
ferred to PVDF membrane (Roche, IN), which was then
incubated with 3% BSA in Tris Buffered Saline, followed
by incubation with the primary antibody against CD105
(C-20, 1:100, Santa Cruz), HIF-1alpha (1:1000, Chemi-
con), or beta-actin (1:1000, Boshide), and then with AP-
labeled secondary antibody (1:2000, goat anti-rabbit or
goat anti-mouse IgG, Santa Cruz). The signals were deter-
mined using the enhanced chemiluminance assay (NBT/
BCIP Array, Huemei Bio, China).
Measurement of tumor cytosolic VEGF165 protein 
concentration
The isolation of tumor cytosolic proteins was performed
by homogenization of tissues as described by Poon [22].
Homogenates were lysed with equal volumes of RIPA lysis
buffer with Cocktail protease inhibitor (1:200, Sigma) on
ice for 30 minutes, and centrifuged at 12,000 rpm at 4°C
for 10 minutes. VEGF165 in the supernatants was quanti-
fied in duplicate by ELISA Kits (Lifekey Corp.) based on a
standard curve generated for each set of samples assayed.
The total protein concentration was determined as
described above. To correct variation caused by the differ-
ent total protein concentrations, the relative level of
VEGF165 was calculated by dividing VEGF165 concentra-
tion by the total protein concentration in each sample.
Real-time PCR
Acid guanidine thiocyanate-phenol-chloroform extrac-
tion was used to isolate total RNA from tissues. With ran-
dom hexamer primers, 1 μg RNA was reverse transcribed
to cNDA with ExScript™ RT reagent Kits (TaKaRa, Japan).
One μg RNA without reverse transcription served as nega-
tive controls. Primers and probes for human CD105 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were
designed with Primer Express 2.0 software (Applied Bio-
systems, Foster City, CA) and synthesized by Genecore
(Shanghai, China). The basic information on the primers
and probes including gene name, NCBI reference, forward
primer, reverse primer, probe and its location between
two exons, product size (bp) were as followings respec-
tively: CD105, NM_000118, CATCCTTGAAGTCCATGTC-
CTCTT, GCCAGGTGCCATTTTGCTT, FAM-
TCCCAACGGGCCCGTCACAG-MGB, 7 and 8, 95;
GAPDH, NM_002046, GGGCTGCTTTTAACTCTGG-
TAAAG, CCATGGGTGGAATCATATTGG, FAM-CCT-
CAACTACATGGTTTAC-MGB, 1 and 2, 103.
Real-time PCR was performed in triplicate for each sample
in a 20-μL-reaction mixture, which consisted of template
DNA (2-μL), and primers (900 nM), probe (250 nM),
Mg2+ (5 mM), and Ex Taq HS (0.1 U/μL, ExScript™ real-
time PCR Kit, TaKaRa). PCR was performed on Stratagene
Mx3005P instrument using the following thermal set-
tings: one cycle of 20 seconds at 95°C, and 55 cycles of 5
seconds at 95°C and 20 seconds at 60°C. Amplification
efficiency (Eff) of each individual sample was calculated
by LinRegPCR program version 7.0 (a gift from Prof.
Pfaffl, Academic Medical Centre, University of Amster-
dam, Amsterdam, the Netherlands). According to the
method tested by Tichopad [23], the relative expression
ratio (RR) of CD105 gene was calculated based on Eff and
the Ct comparative with a reference gene (GAPDH) in a
sample.
Statistical analysis
Data were expressed as mean ± standard deviation with
the range given in parentheses. Statistical analysis was per-
formed using the t tests, ANOVA and linear regression
when data were normally distributed. The Pearson χ2 test
was used to compare the results of two or more sub-
groups. All statistical procedures were performed using
SPSS (Version 11.5 SPSS Inc, Chicago). Values of p < 0.05
were considered as statistically significant.
Results
Characteristics of the HCC patients
In 64 patients (53 males and 11 females, median age 51
yrs) who underwent curative resection (57 cases for regu-
lar hepatectomy and 7 for orthotopic liver transplanta-
tion), the average tumor size was 6.65 ± 4.17 cm (range:
0.8–20 cm). There were 40 patients with large tumor
(maximum diameter > 5 cm), 24 with small tumor (max-
imum diameter ≤ 5 cm), and 22 with multiple tumors
(more than two lesions). Liver cirrhosis was detected in 60
patients, and the remaining 4 patients had chronic hepa-
titis. The etiologies of underlying liver diseases were hep-
atitis B in 56 patients, hepatitis C in 1, mixed viral
infection in 1, alcoholic cirrhosis in 4, and cirrhosis of
unidentified etiology in 3 patients. According to UICCBMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
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recommendations (2002) [19], 25 patients were classified
as stage I, 12 patients as stage II, 26 patients as stage III,
and 1 patient as stage IV. Fifty-two patients were in Child's
class A, 11 in class B, and 1 in class C.
Distribution and expression of CD105 in liver with HCC: 
CD105 rich in non-tumor tissues
In normal liver tissues, expression of the CD105 antigen
was restricted to only a few hepatic sinus endothelial cells
(HSECs) located in the direct vicinity of portal tracts (Fig-
ure 1A). Similar to Ho's report [17], highlighted microves-
sels by CD105 showed three patterns of expression in the
tumor tissue sections: sinusoid-like, branching, and small
without apparent lumina (endothelial sprouts, Figure 1B
and 1C). However, the expression pattern of CD105 in AT
and TF was different from that in TT in the following
aspects. First, CD105 showed a diffuse pattern of staining
in most cases (51/64), predominantly on HSECs in the
surrounding of draining veins (Figure 1C and 1D). Sec-
ond, there were no CD105 positive cells in portal veins,
hepatic arteries or biliary ducts (Figure 1E). Third, besides
in HSECs, some CD105 positive cells, such as on septal
fibroblasts, existed in the surrounding of pseudolobules
in focal nodular hyperplasia (Figure 1F). Furthermore, the
mean score of MVD-CD105 (mean ± SD/0.74 mm2) was
19.00 ± 9.08 in HC, 153.12 ± 53.26 in TF, 191.12 ± 59.17
in AT, and 85.43 ± 44.71 in TT, respectively. MVD-CD105
in HC was significantly lower than in TF, AT, and TT (One-
Way ANOVA, p < 0.001). Paired t test showed that MVD-
CD105 in TF and AT was significantly higher than in TT (p
= 0.012 and p = 0.007, respectively) while there was no
significant difference between TF and AT (Figure 2A).
Previous investigations reported that all antibodies
against CD105 did not show the same specificity [1]. To
examine whether different antibodies to CD105 resulted
in varied immunohistochemical staining, we evaluated
the mRNA level of CD105 in 64 paired specimens by real-
time PCR and CD105 antigen in 16 paired samples by
Western blots with another CD105 antibody (C-20). The
relative level of CD105 mRNA (CD105/GAPDH, mean ±
SD) was 0.0045 ± 0.0009 in HC, 0.076 ± 0.011 in TF,
0.088 ± 0.021 in AT, and 0.029 ± 0.005 in TT, respectively.
CD105 mRNA in HC was significantly lower than in TF,
AT, and TT (One-Way ANOVA, p = 0.001). Paired t test
showed that the CD105 mRNA in AT and TF was signifi-
cantly higher than in TT (p < 0.001 and p = 0.009, respec-
tively) and there was no significant difference between TF
and AT (Figure 2B). Moreover, Western blotting analysis
revealed that the CD105 levels in TF, AT, and TT were
5.02-, 6.98- and 2.14-fold higher than that in HC (n = 8,
p < 0.001), respectively, and CD105 in TF and AT were sig-
nificantly higher than in TT (p = 0.038 and p = 0.027,
respectively; Figure 3).
Consequently it was demonstrated at protein and mRNA
levels that the CD105 was expressed mostly on HSECs
and microvessels, more abundantly in AT and TF than in
TT.
Coincident distribution and expression of HIF-1alpha with 
CD105
The levels of CD105 protein, mRNA and promoter activity
can be up-regulated by hypoxia via the HIF-1 complex,
which binds a functional consensus HRE in the endoglin
promoter [24]. The distribution and expression of HIF-
1alpha in liver tissues with HCC were evaluated by Immu-
nohistochemistry and Western blotting analysis. The pos-
itive staining was located in the cytoplasm and/or the
nuclei of tumor cells and hepatocytes (Figure 4B–D). In
general, the intensity of HIF-1alpha staining in the non-
tumor tissues (TF and AT) was higher than in tumor tis-
sues (Figure 4C). In the portal area of cirrhosis, the expres-
sions of HIF-1alpha in the bile duct and the vessels were
negative (Figure 4D). Among the 64 paired specimens,
HIF-1alpha was expressed in 88.13% of TT, which was
lower than in AT (96.46%) and TF (92.39%), but was
higher than that in normal hepatic tissues (zero, Figure
4A). In accordance with the results of immunohistochem-
ical staining, Western blotting analysis revealed that the
HIF-1alpha levels in TF, AT, and TT were 22.82-, 23.81-,
and 14.79-fold higher than that in HC, respectively (n = 8,
p < 0.001), and the HIF-1alpha levels in TF and AT were
significantly higher than in TT (p = 0.006 and p = 0.001,
respectively; Figure 3).
Correlated distribution and expression of VEGF165 with 
CD105
Previous clinical investigations reported that CD105 cor-
related with VEGF165 in some tumors, such as non-small
cell lung cancer [5], HCC [25], and breast cancer [26]. The
distribution and expression of VEGF165 in liver tissues
with HCC were evaluated by Immunohistochemistry and
ELISA. The positive staining of VEGF165 mainly existed in
cytoplasm of tumor cells and hepatocytes (Figure 5B–D).
In general, the intensity of VEGF165 staining in the non-
tumor tissues (TF and AT) was higher than in tumor tis-
sues (Figure 5C). VEGF165 signals were also present in
endothelial cells (Figure 5D). Among the 64 paired speci-
mens, VEGF165 was positively stained in 37.12% of TT,
which was lower than in AT (56.23%) and TF (47.91%),
but was higher than in normal hepatic tissues (zero, Fig-
ure 5A). In addition, ELISA analysis also revealed that
VEGF165 protein in HC was significantly lower than in TF,
AT, and TT (One-Way ANOVA, p = 0.017). Paired t test
showed that VEGF165 protein in TF and AT was signifi-
cantly higher than in TT (n = 36, p = 0.025, and p = 0.024,
respectively; Figure 6A). Paired correlation analysis
showed that CD105 mRNA correlated with VEGF165 in TFBMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
Page 5 of 10
(page number not for citation purposes)
(r = 0.790, p = 0.002), AT (r = 0.723, p < 0.001), and TT (r
= 0.473, p = 0.048), respectively (Figure 6B).
Discussion
Previous reports of Ho's and ours have demonstrated that
CD105 is a better prognostic marker for HCC than MVD
assessed by a pan-endothelial cell marker CD34 [16,17].
However, our present study showed that CD105 had
lower expression in tumor tissues than in non-tumor tis-
sues with cirrhosis, in which the expression of CD105
antigen was found mostly in HSECs, especially in outflow
area of AT and TF. In agreement with our findings,
Theuerkauf et al [27] revealed the common character of
the distribution of CD105 in liver with three different
pathological conditions (localized increased perfusion,
chronic congestion, decreased portovenous or arteriohe-
patic perfusion): CD105 immunoreactivity was mostly
restricted to HSECs while that in portal blood vessels was
negative. An increased CD105 expression on HSECs and
septal fibroblasts in non-tumor tissues of patients with
chronic liver diseases has been observed [28]. Moreover,
Ho's investigation showed that the disease-free survival in
patients with a diffuse pattern of CD105 staining in AT
was statistically worse than that in patients without a dif-
fuse pattern of CD105 expression [17]. However, Yang et
al reported that CD105 was not expressed in the vascular
endothelial cells of the paracarcinomatous liver tissues in
any of the 113 specimens [25]. Although different anti-
Distribution of CD105 antigen in normal, non-tumor (TF and AT), and tumor tissues Figure 1
Distribution of CD105 antigen in normal, non-tumor (TF and AT), and tumor tissues. A, Immunostaining for 
CD105 in normal tissues. B, Highlighted microvessels by CD105 in tumor tissues. C, Diffuse positive sinusoidal segments found 
in the surrounding of tumor. D, Diffuse positive HSECs in the surrounding of draining veins (CV, central vein) in non-tumor tis-
sues. E, Distribution of CD105 in portal area (PV, portal vein) in non-tumor tissues. F, CD105-positive septal fibroblasts (black 
arrows) in periphery of pseudolobules in non-tumor tissues. The signals were detected by DAB staining. Magnification: ×200.
MVD-CD105 and CD105 mRNA level in normal, non-tumor  (TF and AT), and tumor tissues Figure 2
MVD-CD105 and CD105 mRNA level in normal, non-
tumor (TF and AT), and tumor tissues. A, MVD-CD105 
in HC (n = 8), TF, AT, and TT (n = 64); B, Relative level of 
CD105 mRNA in HC (n = 8), TF, AT, and TT (n = 64) (* = p 
< 0.05, ** = p < 0.01, versus HC; # = p < 0.05, ## = p < 0.01, 
versus TT); Columns, mean; bars, SD.BMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
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bodies to CD105 antigen may result in varied expression
of CD105 in liver with HCC, as well as some other types
of cancer [29-33], the discrepancy of our findings and
Yang's may not be caused by the different antibodies to
CD105 antigen (see below).
To clarify whether above discrepancy was caused by differ-
ent antibodies, we evaluated the protein level of CD105 in
three parts of the specimens from HCC by two different
CD105 antibodies (H-300 and 4C11) and mRNA level by
real-time PCR in the present investigation. All of the
above results showed the similar distribution and expres-
sion. To validate the specificity of antibodies, we further
evaluated the distribution and expression of CD105 in
ductal infiltrative breast cancer, colon cancer, renal cancer,
and their surrounding tissues using above two antibodies.
Of note, there was a significant correlation between
microvessel counts stained by two CD105 antibodies in
breast, colon and renal cancer samples (Figure 3, 4, 5 in
Supplementary Data). In addition, we studied the distri-
bution and expression of CD105 by H-300 and 4C11 anti-
bodies in our own HCC tissue arrays developed in 2006.
The results displayed the same distribution and expres-
sion of CD105 in two tissue array sections (Figure 6 in
Supplementary Data). Therefore, the discrepancy in
immunohistochemical staining with different antibodies
was excluded.
The molecular basis for CD105 up-regulation is not com-
pletely defined, but there is increasing experimental evi-
dence that hypoxia can stimulate CD105  mRNA
expression in vascular endothelial cells via the HIF-1 com-
plex, which binds a functional consensus HRE in the
endoglin promoter [24]. As a key transcript factor under
hypoxia, HIF-1alpha had higher expression in non-tumor
cirrhotic tissues than in tumor tissues in this study (Figure
3 and 4B–D). The distribution and expression of CD105
in liver with HCC was consistent with those of HIF-
1alpha. In a further investigation in 13 cirrhotic liver tis-
sues (CT), the expression pattern of CD105 in CT was sim-
ilar to that in AT and TF (Figure 2 in 1). In this regard,
cirrhosis might induce hypoxia condition in liver tissues.
The non-tumor tissues themselves have precancerous
changes with angiogeneses [34]. During liver cirrhosis,
fibrogenesis induces intrahepatic shunts and the barrier
between the sinusoids and the hepatocytes [35]. Fibrous
pseudo lobes form as discrete hypoxia unit to induce ang-
iogenesis [34]. Furthermore, hepatitis B virus X protein
increases the transcriptional activity and protein level of
Distribution of HIF-1alpha antigen in normal, non-tumor (TF  and AT), and tumor tissues Figure 4
Distribution of HIF-1alpha antigen in normal, non-
tumor (TF and AT), and tumor tissues. Immunostaining 
for HIF-1alpha in HC (A), tumor tissues (B), the surrounding 
of tumor (C), and portal area of non-tumor tissues (D). The 
signals were detected by DAB staining. Magnification: ×200. Relative Expression of CD105 and HIF-1alpha antigens in  normal, non-tumor (TF and AT), and tumor tissues Figure 3
Relative Expression of CD105 and HIF-1alpha anti-
gens in normal, non-tumor (TF and AT), and tumor 
tissues. CD105 and HIF-1alpha antigens were detected by 
Western blotting analysis in 16-paired samples, and the rep-
resentative data were presented. A, Proteins in lanes 1–3 
were extracted from TF, AT, and TT of patient 155, respec-
tively; lanes 4–6 from TF, AT, and TT of patient 167, and 
lanes 7 and 8 from normal tissues of two healthy controls. B, 
Fold of CD105 and HIF-1alpha represented the mean of the 
relative fold from 8 independent experiments (HC, n = 8; TF, 
AT, and TT, n = 16). Relative fold refers to the ratio of 
CD105 or HIF-1alpha intensity in TF, AT, and TT to that in 
HC (* = p <0.05, ** = p < 0.01, versus HC; # = p < 0.05, ## = 
p < 0.01, versus TT). Columns, mean; bars, SD.BMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
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HIF-1alpha, and thereby promote angiogenesis during
hepatocarcinogenesis [36]. Therefore cells in cirrhotic
liver are under a sustained, mechanically reduced blood
flow, which induces angiogenesis in cirrhotic tissues [14].
It has been documented that CD105 correlates with
VEGF165 in some tumors, such as non-small cell lung can-
cer [5], HCC [25], and breast cancer [26]. In this study, we
found that intrahepatic CD105 correlated with VEGF165 in
both tumor tissues and non-tumor tissues (Figure 6). The
fact that decreased oxygen pressure is a strong stimulus for
VEGF transcription and protein synthesis may explain the
up-regulation of the VEGF in the cirrhotic liver [37,38].
Moreover, VEGF expression is also modulated by
cytokines released from the infiltrating inflammatory cells
in surrounding cirrhotic liver tissues [39]. Therefore it is
widely accepted that pro-angiogenic factors, such as
VEGF165 [14,18,39] and HGF [40], have higher expression
in the surrounding tissues than in tumor tissues. We fur-
ther evaluated the distribution and expression of CD105
in 13 cirrhotic liver tissues (CT). The expression pattern of
CD105 in CT was similar to that in TF and AT from HCC
(Figure 2 in Supplementary Data). Taken together, cirrho-
sis might induce hypoxia and the expression of some pro-
angiogenic factors in cirrhotic tissues, and modulate the
expression of CD105 in turn. Of note, MVD in AT is
higher than that in any of HC, CT, TF, and TT. Therefore,
the CD105 over-expression in the tumor free tissue may
be a reflection of both cirrhosis and a "field effect" rele-
vant to the tumor. It is worthy investigating the relevant
mechanism further.
Because of the particular distribution and expression of
CD105 in liver with HCC, targeting for antiangenesis ther-
apy with CD105 antibodies in HCC should be considered
cautiously. Because (1) increased CD105 expression was
not only on endothelial cells in tumor neovessels, but also
on HSECs and septal fibroblasts in non-tumor tissues; (2)
Relative level of VEGF in normal, non-tumor (TF and AT), and tumor tissues and the correlation of VEGF and CD105 Figure 6
Relative level of VEGF in normal, non-tumor (TF and AT), and tumor tissues and the correlation of VEGF and 
CD105. A, Relative level of VEGF in HC (n = 8), TF, AT, and TT (n = 36, * p < 0.05 versus HC; # p < 0.05 versus TT). Col-
umns, mean; bars, SD. B, Correlation between VEGF and CD105 mRNA in TF, AT, and TT (n = 36).
Distribution of VEGF antigen in normal, non-tumor (TF and  AT), and tumor tissues Figure 5
Distribution of VEGF antigen in normal, non-tumor 
(TF and AT), and tumor tissues. Immunostaining for 
VEGF in HC (A), tumor tissues (B), the surrounding of tumor 
(C), and portal area of non-tumor tissues (D). The signals 
were detected by DAB staining. Magnification: ×200.BMC Cancer 2007, 7:122 http://www.biomedcentral.com/1471-2407/7/122
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CD105 immunoreactivity was mostly restricted to the
endothelium of draining veins; (3) CD105 is a cell surface
antigen widely expressed on vascular endothelium, syncy-
tiotrophoblast, some tissue macrophages, and progenitor
cells [41]. Even though the staining in normal mucosa was
weaker than in tumor tissues, all tissues were found to be
positive, at least in microvessels, except for normal breast.
Moreover, a positive reaction was observed in the stroma
of some tissues (glands and reproductive tract) [42].
Because of above concerns, targeting with CD105 in HCC
lacks of specificity, may result in fetal side effects, such as
hemorrhage, liver dysfunction, and interfere with physio-
logical angiogenesis.
Conclusion
Our data showed that the expression of CD105 at mRNA
and protein levels was higher in tumor tissues than in nor-
mal liver, but was lower than in non-tumor tissues with
cirrhosis. Noticeably, CD105 showed a diffuse pattern of
staining predominantly on HSECs in non-tumor tissues.
Therefore, CD105 might not be an appropriate targeting
for antiangenesis therapy in HCC with liver cirrhosis. In
addition, the presence of well-diffuse patterns of CD105
expression in the adjacent non-tumor tissues could pre-
dict its key role during cirrhosis. Further studies are mer-
ited to clarify the mechanisms involved in cirrhosis.
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